Swiss Companies in India: Pharma, Finance & EFTA-India TEPA Benefits

Why Swiss Companies Are Doubling Down on India

Switzerland ranks among India's top 15 foreign investors, with over 330 Swiss companies operating across the country. Cumulative Swiss FDI in India reached USD 9.95 billion between 2000 and 2023, concentrated in pharmaceuticals, financial services, machinery, and sustainable technologies. But the October 2025 activation of the EFTA-India Trade and Economic Partnership Agreement (TEPA) has fundamentally altered the calculus for Swiss businesses evaluating India market entry.

The TEPA is not merely a tariff reduction agreement. It represents a binding commitment by the four EFTA states — Switzerland, Norway, Iceland, and Liechtenstein — to channel USD 100 billion in FDI into India over 15 years, with the first USD 50 billion targeted within the initial decade. The agreement also aims to generate one million direct jobs in India from these investment inflows.

The EFTA-India TEPA: What It Actually Covers

Market Access for Goods

Under the TEPA, EFTA has opened 92.2% of tariff lines — encompassing 99.6% of India's exports — including 100% elimination of duties on non-agricultural products. India's reciprocal offer covers 82.7% of tariff lines, accounting for 95.3% of EFTA exports. However, sensitive sectors are explicitly protected on the Indian side, including pharma, medical devices, processed food, dairy, soya, coal, and sensitive agricultural products. This protection means Swiss pharmaceutical exporters cannot simply flood the Indian market with finished dosage forms at zero duty — the competitive advantage lies in active pharmaceutical ingredients (APIs), specialty chemicals, and high-value biologics.

Services and Professional Mobility

The TEPA includes provisions for Mutual Recognition Agreements (MRAs) in professional services such as nursing, chartered accountancy, and architecture. For Swiss financial services firms, this creates structured pathways for deploying professionals to Indian operations. The agreement's 14 chapters also address intellectual property rights, transfer pricing considerations, and trade facilitation measures that reduce compliance friction for cross-border transactions.

The Dedicated EFTA Desk

Operational since February 2025, a dedicated EFTA Desk functions as a single-window mechanism for investment facilitation, supporting EFTA businesses in investing, expanding, and establishing operations in India. Swiss companies can use this desk to navigate regulatory approvals, understand sector-specific FDI rules, and connect with relevant Indian government agencies.

Swiss Pharma Giants in India: Current Operations

Novartis

Novartis maintains a significant Indian presence through Novartis India Limited, listed on the Bombay Stock Exchange. The company's Indian operations span oncology, ophthalmology, and immunology portfolios. However, Novartis has historically faced challenges in India around patent protection — the Supreme Court's 2013 rejection of Novartis's patent application for Glivec (imatinib mesylate) under Section 3(d) of the Indian Patents Act remains a landmark case. Under the TEPA's strengthened IP provisions, Swiss pharma companies may find improved predictability in patent prosecution timelines.

Roche

On October 1, 2025 — the very day TEPA came into force — Roche Pharma announced a commitment to invest 1.5 billion Swiss francs (approximately INR 17,000 crore) in India over five years. This investment targets diagnostics infrastructure, clinical research centres, and digital health capabilities. Roche's Indian operations already include a Global Information Solutions centre in Pune and commercial operations for its oncology and diagnostics portfolios.

Other Swiss Pharma Presence

Beyond the big names, Swiss pharma companies like Helsinn (which has an exclusive licensing agreement with Glenmark for Akynzeo I.V. in India), Lonza (contract manufacturing), and numerous Swiss biotech firms are leveraging India both as a market and as a clinical trial hub. In November 2025, a Swiss pharma and biotech delegation visited India to explore R&D cooperation and expanded investment opportunities in India's healthcare sector.

Swiss Finance in India: Banking, Insurance, and Asset Management

Switzerland's financial sector presence in India includes UBS (wealth management and investment banking), Zurich Insurance (general insurance through a joint venture), and Swiss Re (reinsurance). The 2025-26 Union Budget's increase of the FDI limit in insurance from 74% to 100% — provided premiums are reinvested in India — creates significant opportunities for Swiss insurers to take full ownership of their Indian operations.

The MFN Clause Suspension: Tax Implications

A critical development affecting Swiss financial flows to India is Switzerland's suspension of the Most Favoured Nation (MFN) clause in the India-Switzerland Double Taxation Avoidance Agreement (DTAA), effective January 1, 2025. This suspension doubled the withholding tax rate on dividends paid to Swiss entities from 5% to 10%. The decision followed the Indian Supreme Court's 2023 ruling that the MFN clause does not automatically apply when a country joins the OECD.

The practical impact is significant. A Swiss parent company receiving INR 10 crore in dividends from its Indian subsidiary now faces INR 1 crore in withholding tax instead of INR 50 lakh — an additional INR 50 lakh annual cost. Companies should review their DTAA structuring and consider whether intercompany pricing adjustments or alternative repatriation mechanisms might mitigate this impact.

Current India-Switzerland DTAA Rates

For income accruing during the 2018-2024 tax years, the reduced 5% dividend rate continues to apply — this transitional provision is important for companies still resolving prior-year assessments.

Entity Structure Options for Swiss Companies

Swiss companies entering India must select from several entity structures, each with distinct regulatory, tax, and operational implications:

Wholly Owned Subsidiary (WOS)

The preferred route for most Swiss manufacturers and pharma companies. A wholly owned subsidiary as a Private Limited Company provides full operational control, limited liability, and eligibility for government incentives like the Production-Linked Incentive (PLI) scheme. Registration requires filing SPICe+ form with the MCA, obtaining a Digital Signature Certificate, and appointing at least one resident director.

Branch Office

Swiss companies that want to test the Indian market without full subsidiary incorporation can establish a branch office with RBI approval. Branch offices can execute contracts, provide professional services, and conduct research — but cannot engage in manufacturing or retail trading. The branch office vs subsidiary comparison is critical for Swiss companies weighing market entry options.

Joint Venture

Particularly relevant for Swiss companies in regulated sectors. A joint venture with an Indian partner provides local market knowledge, regulatory navigation expertise, and established distribution networks. Swiss insurance companies like Zurich have historically used this model in India.

FDI Routes and Sectoral Caps

Most sectors relevant to Swiss investors — pharmaceuticals (greenfield), IT services, financial services, and manufacturing — permit 100% FDI under the automatic route, meaning no prior government approval is required. Key exceptions include:

• Pharmaceuticals (brownfield): Up to 100% FDI permitted, but brownfield acquisitions require government approval via FC-GPR filing
• Insurance: Now 100% FDI permitted (increased from 74% in 2025-26 Budget), with reinvestment conditions
• Multi-brand retail: 51% cap with government approval
• Defence: 74% under automatic route, 100% via government approval for critical technologies

Swiss companies must file FC-GPR within 30 days of share allotment and submit the Annual FLA Return to RBI by July 15 each year. Non-compliance attracts penalties under FEMA that can reach up to three times the amount involved.

Tax Planning for Swiss-Indian Operations

Corporate Tax Rates

For FY 2025-26, the effective corporate tax rate for new manufacturing companies incorporated after October 1, 2019 is 17.16% (15% base rate plus surcharge and cess). Existing companies pay an effective rate of approximately 25.17%. Foreign companies operating through branch offices face a 35% corporate tax rate (reduced from 40% by the Finance Act 2024, effective from 1 April 2024) plus surcharge and cess.

Transfer Pricing Considerations

Swiss-Indian intercompany transactions — particularly for pharma API transfers, technology licensing, and management services — are subject to India's transfer pricing regulations. The Finance Bill 2025 introduced block transfer pricing assessments effective April 2026, where the arm's length price determined for an international transaction applies for a block period of three financial years. Swiss companies should ensure their transfer pricing documentation covers all transactions with Indian entities, including cost-sharing arrangements for R&D and shared services.

GST Implications

Swiss companies establishing operations in India must obtain GST registration in each state where they maintain a place of business. Pharmaceutical products attract GST rates ranging from 5% (essential medicines on the National List of Essential Medicines) to 12% (most other pharmaceutical products). Medical devices attract 12% GST. Import of services from Swiss entities triggers reverse charge GST at 18%.

Practical Steps: Setting Up a Swiss Subsidiary in India

1. Obtain Digital Signature Certificates (DSC): For all proposed directors, including the Swiss parent company's nominees. Timeline: 2-3 days.
2. Reserve company name: Via RUN (Reserve Unique Name) service on MCA portal. Timeline: 1-2 days.
3. File SPICe+ form: Integrated incorporation form covering company registration, PAN, TAN, EPFO, ESIC, and bank account opening. Timeline: 5-7 days.
4. Appoint resident director: At least one director must be an Indian resident (stayed in India for 182+ days in the financial year).
5. Open bank account: With authorised dealer bank for receiving FDI inflows. Minimum initial deposit typically INR 1 lakh.
6. File FC-GPR: Within 30 days of share allotment to the Swiss parent. Filed through the RBI's FIRMS portal.
7. Obtain IEC: If importing pharma raw materials, APIs, or equipment, apply for Import Export Code from DGFT.
8. GST registration: Apply within 30 days of becoming liable to registration.

Total timeline from decision to operational entity: 45-60 days, assuming all documentation is in order. Engaging a foreign subsidiary registration service can reduce this to 30-40 days.

Annual Compliance Calendar

Once operational, Swiss subsidiaries in India must maintain a rigorous compliance schedule. Key dates include: quarterly advance tax instalments (June 15, September 15, December 15, March 15), monthly GST return filing (GSTR-1 by the 11th and GSTR-3B by the 20th of each month), annual ROC filings within 30-60 days of the Annual General Meeting, annual income tax return by October 31 for transfer pricing cases, and the FLA Return to RBI by July 15. Missing any of these deadlines triggers automatic penalties, interest charges, and in some cases director disqualification. Swiss companies should invest in a robust annual compliance management framework from day one of Indian operations.

Swiss Precision Engineering and Technology Companies

ABB India

ABB, headquartered in Zurich, operates one of its largest global footprints in India through ABB India Limited. The company manufactures electrification products, industrial automation systems, robotics, and power grid solutions across multiple Indian manufacturing facilities. ABB India's revenues have grown significantly as India's manufacturing sector modernises under the Make in India initiative. The TEPA's elimination of duties on industrial equipment from EFTA countries creates opportunities for ABB to import advanced components for assembly in India at reduced costs.

Nestle India

Nestle India, a subsidiary of the Swiss food giant, operates eight manufacturing facilities and is one of the largest FMCG companies in India with revenues exceeding INR 19,000 crore. While food products remain protected under the TEPA's sensitive list, Nestle's established Indian manufacturing base positions it to benefit from reduced input costs on imported Swiss-origin packaging materials, flavourings, and food-grade chemicals that fall outside the sensitive category.

Other Swiss Technology Companies

Holcim (through its subsidiary ACC and Ambuja Cements), Sika (construction chemicals), Givaudan (flavours and fragrances), and Schindler (elevators) all maintain substantial Indian operations. These companies collectively employ tens of thousands of Indian workers and contribute to India's manufacturing GDP. The TEPA's investment facilitation provisions, including the dedicated EFTA Desk, streamline expansion processes for these companies when they add capacity or enter new product segments in India.

Common Mistakes Swiss Companies Make in India

Based on our advisory experience, Swiss companies frequently encounter these pitfalls when establishing Indian operations:

• Underestimating compliance complexity: India requires over 30 different regulatory filings annually for a typical manufacturing subsidiary. Swiss companies accustomed to streamlined European compliance often understaff their Indian compliance teams, leading to penalties and delayed approvals
• Ignoring state-level incentives: Each Indian state offers different investment incentives, land subsidies, and tax holidays. Swiss companies that default to Mumbai or Delhi without evaluating alternatives like Gujarat, Karnataka, or Tamil Nadu may miss substantial cost savings
• Patent strategy gaps: India's Section 3(d) sets a higher bar for pharma patents than Swiss companies are accustomed to in European markets. Filing a comprehensive patent strategy that accounts for Indian-specific requirements from the outset is essential
• DTAA rate assumptions: Assuming the pre-2025 MFN rates still apply for dividend withholding results in incorrect tax provisioning. Swiss companies must update all intercompany payment calculations to reflect the 10% rate
• Transfer pricing documentation delays: Indian transfer pricing documentation must be contemporaneous — preparing it retrospectively after a tax audit notice is both more expensive and less effective. Swiss parent companies should establish documentation protocols at the time of subsidiary incorporation

Key Takeaways

• The EFTA-India TEPA, effective October 2025, eliminates duties on 100% of non-agricultural products from India to EFTA and commits USD 100 billion in FDI to India over 15 years
• Switzerland's MFN clause suspension from January 2025 doubled dividend withholding tax from 5% to 10% — review your DTAA strategy accordingly
• Over 330 Swiss companies already operate in India with cumulative FDI of USD 9.95 billion — the TEPA and EFTA Desk further reduce entry barriers
• Swiss pharma companies benefit from India's PLI scheme, growing clinical trial infrastructure, and strong API manufacturing base — but patent enforcement under Section 3(d) remains a consideration
• Insurance sector FDI limits increased to 100% in 2025-26, creating full ownership opportunities for Swiss insurers like Zurich Insurance and Swiss Re
• New manufacturing subsidiaries enjoy a 17.16% effective tax rate — among the lowest in Asia for pharma and precision engineering investments